Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment

Print
| Source: Puration, Inc.

DALLAS, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Puration, Inc. (USOTC:PURA) Today announced plans to produce a THC infused beverage in Canada in conjunction with a previously announced pending acquisition intended to establish a cannabis cultivation operation for the recreational marijuana market expected to be legalized nationwide in Canada this summer.  The new THC infused beverage will expand Puration’s current cannabis infused beverage business.  Last year, Puration introduced EVERx, a CBD infused sports water. The sales of EVERx yielded over a 60% gross margin as reported in the company’s 2017 annual report. The initial sales have won the interest of additional distributors to include a recently announced national distribution contract. Puration has designed a THC infused beverage and registered the name THCSavor.  Package design is underway.  Highlights of the THCSavor go-to-market plan are to be included in the upcoming shareholder presentation scheduled for, Thursday next week, on May 10th, to provide overall details on the Canadian business acquisition expected to be closed as early as the end of this week.

For more information on Puration, visit http://www.aciconglomerated.com.
Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
+1-800-861-1350